Skip to main content
. 2019 Oct 11;10:2411. doi: 10.3389/fimmu.2019.02411

Figure 6.

Figure 6

(A) The mCherry signal at the injection site of CT26.WT cells over time (normalized to the signal at day 2). Mice immunized with the DNA vaccine in which RSV-F is fused to the B. pseudomallei antigens Hcp1 and TssM (vac-C) eliminated tumor cells expressing the bacterial antigens more quickly than mice immunized with vaccines that did not include RSV-F, and non-immunized animals. Combining vac-B and vac-C [vacB/C] (Group 5, closed diamonds) resulted in the most rapid clearance (n = 6 animals per group) (Asterisks (*) are color coded to match each individual animal group; horizontal asterisks indicate no significant difference between groups at that particular time point; vertical asterisks indicate a significant difference between indicated groups at a p-value < 0.05). Antibody titers against Hcp1 and TssM (B) and IL-2 levels (C) in the sera of immunized mice 12 days after challenge with CT26.WT cells stably expressing Hcp1/TssM. “Control” represents antibody titers or IL-2 levels in non-immunized (PBS-treated) mice challenged with the same CT26.WT cells (n = 6, *P < 0.05). (D) In vitro cytotoxicity assay against CT26.WT cells expressing Hcp1/TssM. PBMC from the mice vaccinated with the combined vaccine vac-B/C showed the highest cytotoxic potential (~18% specific cytotoxicity). PBMC from animals immunized with DNA vaccine harboring the cytosolic antigen vac-A demonstrated the least amount of antigen specific cytotoxicity. Control, cytotoxicity of PBMC from non-immunized mice (n = 6, *P < 0.05).